Exceptional result indeed! Sensitivity increased from 77% to 84%. RHY ColoSTAT test-kits would meet requirements for reimbursement eligibility in the US based on 84% sensitivity and 94% specificity. Noting US is a huge market.
Study 6 objectives have been met - demonstrated the analytical performance of the test-kits manufactured by third party and has exceed previous results (based on 300 blood samples). Opportunity to further improve results for Study 7 with continuous improvements of RHY’s proprietary algorithms read using machine intelligence (AI)
Ann: Study 6 Successfully Concluded - Exceptional Results, page-7
Add RHY (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $27.34M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.0¢ | 11.0¢ | $2.291K | 20.83K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 23335 | 3 |
View Market Depth
| Last trade - 11.54am 08/11/2024 (20 minute delay) ? |
| RHY (ASX) Chart |